German Merger Control for Cross‑border M&A (2026): When to Notify, Thresholds, Timelines and Filing Strategy

Last updated: September 2026 (procedural update)

Merger control germany is one of the first regulatory questions any cross‑border deal team must answer, because a mistaken jurisdictional call can add months to closing or trigger fines for premature completion. This guide takes a clear position: for cross‑border M&A involving German turnover you must run the threshold arithmetic early, choose the correct forum decisively, and build your filing strategy around the standstill obligation rather than treating clearance as an afterthought. Below you will find an at‑a‑glance decision table, worked threshold examples, realistic Phase I and Phase II timelines, and sample closing‑protection clauses. This is general information, not legal advice; the attributed expert can advise on specific transactions.

Executive summary: the three decisions that matter

Before you read the detail, fix these three points in the deal timetable. They drive almost every downstream choice in merger control germany.

• Choose the right forum. If the transaction meets the EU Merger Regulation (EUMR) community turnover thresholds, you file once with the European Commission and national filings fall away under the one‑stop‑shop. If only the German thresholds under the Gesetz gegen Wettbewerbsbeschränkungen (GWB) are met, you notify the Bundeskartellamt.
• Respect the standstill. Both regimes are suspensory, you cannot implement the concentration before clearance. Build conditions precedent and a realistic long‑stop date around Phase I and, where competitive overlaps exist, a possible Phase II.
• Prepare remedies and FDI coordination in parallel. Where overlaps are material, open early dialogue on remedies and sequence any German foreign direct investment (FDI) screening alongside the antitrust filing so neither becomes the bottleneck.

One‑line takeaway: in merger control germany, jurisdiction and timing are decided by turnover arithmetic done early, do the maths in the term‑sheet phase, not in the deal room.

At‑a‑glance decision table

Jurisdictional choice in merger control germany: Bundeskartellamt vs European Commission

The single most consequential decision in any cross‑border filing is which authority reviews the deal. The EUMR operates a one‑stop‑shop: where the community‑dimension thresholds are met, the European Commission has exclusive jurisdiction and you do not file separately in Germany or any other member state. Where those thresholds are not met but the German GWB thresholds are, the Bundeskartellamt reviews the concentration. This is a binary allocation in principle, but real deals throw up consolidation questions, minority stakes and referral mechanisms that blur the edges. Getting the allocation right protects your timetable; getting it wrong can mean a wasted filing, a late correction, and closing delay.

Legal tests: national GWB thresholds vs EUMR

Under the EUMR (Council Regulation (EC) No 139/2004), a concentration has a community dimension when combined aggregate worldwide and EU‑wide turnover exceed the Regulation’s thresholds. Under the GWB, notification to the Bundeskartellamt is required where the parties’ combined worldwide turnover and their German turnover figures cross the statutory levels, subject to the domestic‑effects and de minimis carve‑outs. The tests are cumulative within each regime: you must satisfy every limb, not just one. Because the two regimes use different turnover baskets, a transaction can qualify for one and not the other, which is precisely why the arithmetic must be run for both before you commit to a forum.

The GWB also contains a transaction‑value threshold that can catch deals with limited target turnover but a high purchase price and significant domestic activity, confirm its current terms in the consolidated statute.

Referral and jurisdictional disputes

The EUMR referral rules bridge the two systems. Under Article 4(5), notifying parties can request that a case capable of review in at least three member states be handled by the Commission instead, avoiding multiple national filings. Article 22 allows one or more member states to ask the Commission to examine a concentration that affects trade between member states even where EU thresholds are not met; note that following the Court of Justice’s Illumina/Grail judgment, the Commission cannot accept Article 22 referrals of transactions that do not meet the referring member state’s own national thresholds.

These mechanisms matter for cross‑border M&A germany deals with pan‑European overlaps: a referral can convert several national reviews into a single EU process, delivering one remedy and one decision rather than divergent national outcomes.

Practical consequences of choosing the wrong forum

Filing in the wrong forum is not a neutral error. If you notify the Bundeskartellamt when the Commission had exclusive jurisdiction, the national clock does not cure the EU obligation, and vice versa. The suspensory obligation runs against the correct authority regardless of where you actually filed. A misfiling therefore risks both delay and, if you close in reliance on the wrong clearance, exposure to gun‑jumping enforcement. The safe practice is to document the threshold analysis in a short jurisdiction memo before signing, and to open a pre‑notification contact where the position is genuinely borderline.

Comparison table: Bundeskartellamt vs European Commission

Decision framework: which forum to choose

The Bundeskartellamt reviews the deal when:

• The transaction meets German turnover (or transaction‑value) thresholds but not the EUMR community thresholds.
• The main competitive overlaps are domestic and any remedies will be national in scope.
• National clearance without EU‑level litigation exposure is expected.

The European Commission reviews the deal when:

• The EUMR community thresholds are met, or likely met after consolidating the acquirer group’s turnover.
• The transaction has overlaps in several member states or a risk of divergent national remedies.
• A single EU remedy package is preferable and referrals or multi‑state enforcement interest are anticipated.

Tactical hybrid: where thresholds are borderline, open a pre‑notification dialogue with the relevant authority, prepare documents capable of supporting either filing, and be ready to request or accept a referral.

Notification thresholds and how to calculate them (with worked examples)

Threshold calculation is where merger control germany decisions are actually made. The arithmetic determines whether you file at all, and if so, where. Work through the tests in a fixed order: first the EUMR community thresholds, then the German GWB thresholds (including the transaction‑value alternative), then the special cases of minority acquisitions and joint control. Because the two regimes look at different turnover baskets, you should run both calculations even when you expect only one to apply, a large acquirer group can push a modest target deal across the EU line unexpectedly.

What counts as turnover (consolidation rules)

Turnover is measured at group level, not just at the level of the entity being bought or sold. Under both the GWB and the EUMR, you consolidate the turnover of the entire controlling group of each party, parents, subsidiaries and jointly controlled entities are aggregated according to the consolidation rules. For the acquirer, this means the whole buying group’s turnover counts, including a private equity sponsor’s wider portfolio where the sponsor exercises control. For the target, only the business being acquired is counted, not the seller’s retained operations. Intra‑group turnover is excluded to avoid double counting. Financial‑sector entities apply special turnover definitions.

These rules explain why a mid‑market target can trigger notification: the acquirer’s group turnover, not the target’s, often does the heavy lifting.

Two worked examples

Example A, EU‑wide (Commission jurisdiction). A US industrial group with worldwide turnover of €6.5 billion acquires a European components business with worldwide turnover of €400 million. Combined worldwide turnover is €6.9 billion, comfortably above the EUMR headline worldwide threshold. Assume the buyer generates €1.2 billion of EU‑wide turnover and the target €280 million, so each has substantial EU‑wide turnover and neither achieves more than two‑thirds of its EU turnover in a single member state. On these facts the community‑dimension test is met: the parties file a single Form CO with the European Commission, and no separate German notification is required under the one‑stop‑shop. Always confirm the figures against the current EUMR limbs before relying on the calculation.

Example B, Germany‑only (Bundeskartellamt jurisdiction). A German Mittelstand manufacturer with worldwide turnover of €300 million acquires a competitor generating €90 million worldwide, of which €60 million is earned in Germany. The buyer earns €200 million of its turnover in Germany. Combined worldwide turnover of €390 million is below the EUMR worldwide threshold, so there is no EU dimension. On these facts the German turnover limbs are satisfied: combined worldwide turnover exceeds the higher GWB limb, one party’s German turnover exceeds the higher domestic limb (buyer €200m) and the second party’s German turnover exceeds the second domestic limb (target €60m). The transaction is notifiable to the Bundeskartellamt. Verify each numerical limb against the consolidated GWB text before relying on the analysis.

These figures illustrate method, not a substitute for statutory verification, always confirm the current numerical limbs in the consolidated GWB text and the EUMR before relying on a calculation.

Timing, Phase I / Phase II and practical timetable risks

Timing drives deal certainty. The suspensory nature of merger control germany means the concentration cannot be implemented until clearance, so the review period is a hard constraint on closing. The clock only starts on a complete notification, which is why pre‑notification preparation is as important as the formal review itself. In outline, the process runs: pre‑notification preparation → formal notification → Phase I (initial review) → clearance, or opening of Phase II (in‑depth review) → clearance, conditional clearance or prohibition.

Bundeskartellamt timeline specifics and fast‑track options

The Bundeskartellamt conducts its Phase I review within one month of receiving a complete notification. Straightforward cases with no competitive concerns are frequently cleared well inside that period, and many unproblematic transactions receive clearance in a matter of weeks. If the authority identifies issues warranting closer examination, it opens Phase II (the main examination proceedings), extending the total review to several further months from notification, extendable where the parties consent or offer commitments. The single greatest timetable risk is an incomplete filing: if the notification is not complete, the one‑month clock does not run. Practical mitigation is a thorough internal completeness check and, for anything with overlaps, an informal pre‑filing contact to align on scope.

Fast, clean clearance is realistic for deals without horizontal or vertical overlaps, which is why an honest overlap assessment before filing pays for itself.

European Commission timeline specifics and remedies timeline

At EU level, Phase I runs for 25 working days from notification, extended to 35 working days where remedies are offered in Phase I or a member state requests referral. If serious doubts remain, the Commission opens Phase II, which lasts a further 90 working days, extendable by 15 or 20 working days in defined circumstances, and further extendable at the parties’ request. Remedies offered late in Phase II extend the deadline. Because the EU process front‑loads pre‑notification, deal teams routinely spend weeks in structured pre‑notification before the formal clock starts. Building this hidden period into the timetable is essential; underestimating it is the most common EU timing error.

Common timetable risks and mitigation playbook

Recurring risks are incomplete filings, mid‑review information requests that stop the clock, unexpected third‑party complaints, and remedy negotiations that push the review into extension. Mitigate with a realistic long‑stop date and disciplined conditions precedent. Sample condition‑precedent language: “Completion is conditional upon receipt of unconditional clearance, or clearance subject only to conditions reasonably acceptable to the Buyer, from the Bundeskartellamt (or, where applicable, the European Commission), such clearance being deemed obtained on expiry of the applicable statutory review period without a decision to open in‑depth proceedings.”

Filing mechanics and practical filing strategy

A disciplined filing strategy shortens the review and reduces the risk of the clock restarting. The core principle in merger control germany is that quality and completeness at notification are worth more than speed to file. A clean, internally consistent filing that pre‑empts the authority’s obvious questions clears faster than a rushed one that invites information requests. Build the filing package during pre‑notification, not after.

Who signs, who files and language requirements

The notifying party is ordinarily the acquirer, though joint control acquisitions require joint notification. Advisers typically file under a power of attorney, so confirm signing authority early. The Bundeskartellamt requires filings in German, which means turnover data, contracts and internal documents must be translated or summarised in German, and translation lead time must be built into the timetable. The European Commission accepts any EU official language and, in practice, English is standard for cross‑border deals. Prepare a consistent factual narrative across both regimes so a hybrid or referral scenario does not require you to rewrite the substance.

Managing parallel filings and waivers

Cross‑border deals often trigger filings in several jurisdictions at once. Coordinate them so the German or EU review does not diverge from parallel foreign reviews on market definition or remedies. Where confidential information is shared with authorities in different jurisdictions, waivers allow regulators to exchange information and align their analysis, granting them can speed alignment but should be given deliberately. Use a filing tracker to sequence submissions, manage redactions consistently, and avoid inconsistent statements between filings that a complainant could exploit. Provisional deal structures and information blockers between the parties help preserve the suspensory position while diligence continues.

Remedies, interim measures and closing mechanics

Where a concentration raises competition concerns, clearance may be conditional on remedies. Understanding the remedy landscape early lets you price and structure the deal to protect the buyer. The Commission’s remedies notice sets out what is acceptable under the EUMR, and the Bundeskartellamt applies a comparable structural‑preference logic in merger control germany matters.

Negotiating divestiture and behavioural remedies

Remedies fall into two families. Structural remedies, typically divestiture of a business or asset, are the authorities’ preferred solution because they resolve the concern cleanly and require no ongoing monitoring. Behavioural remedies, such as access, supply, non‑discrimination or interoperability commitments, are accepted where they address the concern effectively, but they carry monitoring burdens and are treated with more caution. Under the Commission’s remedies framework, structural commitments are favoured and the divestiture package must be viable, standalone and capable of attracting a suitable purchaser. Practical negotiation tactics include identifying the divestiture perimeter early, lining up potential purchasers before offering the remedy, and, where the authority demands certainty, offering an upfront‑buyer or fix‑it‑first solution to remove execution risk.

Consequences for closing and buyer protections (W&I interface)

Remedies reshape closing mechanics. If a divestiture is required, the sale‑and‑purchase agreement must allocate the risk and cost of that divestiture between the parties, define what conditions are “reasonably acceptable,” and set a hell‑or‑high‑water or best‑efforts standard for obtaining clearance. Protect the buyer with a holdback or escrow against remedy costs and with a walk‑away right if the required remedy exceeds a materiality threshold. Sample holdback language: “An amount equal to [X] shall be retained in escrow pending completion of any divestiture required as a condition of clearance, to be released to the Seller only upon the Buyer’s confirmation that the relevant commitments have been satisfied without material adverse cost to the Buyer.

” Warranty and indemnity (W&I) insurance rarely covers regulatory remedy risk, so this must be handled in the transaction documents rather than assumed away in the policy.

Coordination with FDI screening and other clearances

For many cross‑border deals, antitrust clearance is only one of two regulatory gates. Germany operates a foreign direct investment screening regime under the Foreign Trade and Payments Act (Außenwirtschaftsgesetz, AWG) and its implementing Ordinance (Außenwirtschaftsverordnung, AWV), administered by the Federal Ministry for Economic Affairs and Climate Action (BMWK), which can review acquisitions by non‑German (in the sensitive sectors, non‑EU/EFTA) investors. FDI screening and merger control run on separate legal bases and separate clocks, so treating them as one process is a mistake. The two reviews can proceed in parallel, but each must be satisfied before closing where both apply, and the later of the two clearances effectively sets the closing date.

Practical sequencing checklist

• Assess both antitrust notifiability and FDI reviewability at the term‑sheet stage, because foreign acquirer status can trigger FDI screening even where competition concerns are minimal.
• File both in a coordinated sequence so neither becomes an avoidable bottleneck; where the FDI review is likely slower, initiate it first.
• Keep the factual narrative consistent across both filings to avoid contradictory positions.
• Set conditions precedent that require both clearances, and calibrate the long‑stop date to the slower process.
• Decide in advance whether conditional FDI clearance with mitigation commitments is acceptable, and reflect that tolerance in the deal documents.

Practical tips, red flags and post‑clearance obligations

Clearance is not the end of the story. After a conditional clearance, the parties carry ongoing obligations: implementing agreed remedies to the authority’s satisfaction, reporting to monitoring trustees where appointed, and honouring behavioural commitments for their full duration. Red flags to watch during and after the process include third‑party complaints that can prompt further scrutiny, public disclosure obligations that may reveal deal details before you are ready, and any temptation to integrate the businesses before clearance, which risks gun‑jumping enforcement under both the GWB and the EUMR. Maintain internal information blockers until clearance, keep a clear record of remedy compliance, and treat monitoring obligations as live commitments rather than closing formalities.

Conclusion and recommended next steps

Merger control germany rewards early, disciplined analysis. The deals that close on time are the ones where the threshold arithmetic was run at term‑sheet stage, the forum was chosen decisively, and the standstill drove the closing structure rather than surprising it. Take three concrete steps now: first, produce a short jurisdiction memo confirming whether you file with the Bundeskartellamt, the European Commission, or must open a pre‑notification dialogue; second, build a realistic timetable that includes pre‑notification and a Phase II contingency; third, agree the remedy‑risk allocation and FDI sequencing in the transaction documents before signing. This is general information, not legal advice, contact the attributed expert via Global Law Experts to pressure‑test your filing strategy on a live transaction.

For the broader deal context, see our International M&A Lawyers, Practical Guide 2026 and the author profile of Dr. Benno A. Packi.

Sources

1. Bundeskartellamt, Merger Control overview & guidance
2. Gesetz gegen Wettbewerbsbeschränkungen (GWB, consolidated text)
3. European Commission, Mergers: Overview
4. Council Regulation (EC) No 139/2004 (EUMR), EUR-Lex
5. Commission notice on remedies acceptable under Council Regulation (EC) No 139/2004, EUR-Lex
6. Außenwirtschaftsgesetz (AWG), consolidated text
7. Bundesministerium für Wirtschaft und Klimaschutz (BMWK), investment screening information
8. Bundeskartellamt, Decisions / Case database (Merger decisions)